Bilateral Acute Iris Transillumination Associated with Moxifloxacin Antibiotic Use

Ocul Immunol Inflamm. 2023 Aug 31:1-6. doi: 10.1080/09273948.2023.2246543. Online ahead of print.

Abstract

Purpose: To describe the clinical and demographic characteristics and associated factors leading to bilateral acute iris transillumination (BAIT) syndrome.

Methods: A retrospective review of patients with BAIT syndrome was performed.

Results: Thirty-five patients with a diagnosis of BAIT were identified. The median age at presentation was 53 years; 80% of the patients were female. Twenty-six patients (74%) had recent histories of systemic antibiotic treatment. Of those with such a history, 24 patients (92%) had been receiving moxifloxacin. Two patients within our cohort were prescribed moxifloxacin prophylactically prior to a systemic surgical procedure and had no evidence of systemic illness or recent viral illness.

Conclusions: Our data support the notion that moxifloxacin might be associated with the onset of BAIT syndrome. Notably, within our cohort, two patients received moxifloxacin as surgical prophylaxis and subsequently developed BAIT syndrome. This could suggest a potential association between moxifloxacin and the onset of BAIT, though further studies are needed to confirm this finding.

Keywords: BAIT syndrome; Bilateral acute iris transillumination; glaucoma; moxifloxacin; uveitis.